Showing posts with label early detection and screening. Show all posts
Showing posts with label early detection and screening. Show all posts
Thursday, March 08, 2012
open access: Nature Reviews: Key Advances in Medicine - Ovarian Cancer/Markman page 15-16
Key Advances in Medicine (book)
Nature Reviews Clinical Oncology (page 15)S11 ovarian cancer | Mutations and non-inferiority analyses show a way forward Maurie Markman (page 15-16)
Highly clinically relevant ovarian cancer clinical research in 2011 focused on an increased understanding of the biology of the malignancy, limitations of strategies for early detection and screening, and the provocative reports of alternative primary and second-line management strategies.
"Although there were a number of very interesting
preliminary reports of therapeutic
advances in ovarian cancer in 2011 (for
example, bevacizumab in the first-line and
second-line management of the malignancy,
and olaparib (Blogger's Note: links to Olaparib (parp inhibitor) - Cancer Research UK) as maintenance therapy for
high-grade serous cancers), as of the writing
of this commentary these studies have not
appeared in the peer-reviewed oncology literature......."
Key advances
■■ There are currently no evidence-based
data supporting the clinical utility of any
ovarian cancer screening strategy in
non‑high-risk populations1
■■ Provocative data suggest there may be a
clinically meaningful difference between
the presence of a BRCA1 or a BRCA2
mutation in influencing outcome in ovarian
cancer6
■■ Under specific circumstances (for example,
neuropathy) it might be reasonable to
substitute pegylated liposomal doxorubicin
for paclitaxel in the front-line chemotherapy
management of ovarian cancer7
Markman, M. Nat. Rev. Clin. Oncol. 9, 69–70 (2012); published online 20 December 2011; doi:10.1038/nrclinonc.2011.200
~~~~~~~~~~~~~
"The articles included in Nature Reviews Key Advances in
Medicine were originally published in the February 2012
issues of the eight clinical Nature Reviews journals. The journals’
editors commissioned international experts to write a short
essay highlighting up to five key papers that made the biggest
contribution to their field in 2011."
add your opinions
BRCA
,
early detection and screening
,
high grade serous
,
markman
,
Olaparib
,
ovarian cancer biology
,
PARP inhibitors
,
recurrent ovarian cancer
Subscribe to:
Posts
(
Atom
)